不同分子分型乳腺浸潤性導管癌中的P53、表皮生長因子受體及Ki-67的表達及意義_《華西醫學》

作者：

王雷 ,  宋林紅 , 朱鴻 , 付靜 , 李科

四川省醫學科學院·四川省人民醫院病理科（成都，610072）;

關鍵詞：

乳腺腫瘤癌，導管，浸潤性免疫表型分型 P53 表皮生長因子受體人類表皮生長因子受體2 Ki-67

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討不同分子分型乳腺浸潤性導管癌手術病例標本中P53、表皮生長因子受體（EGFR）和Ki-67的表達及臨床意義。方法　采用免疫組織化學鏈霉菌抗生物素蛋白-過氧化物酶連接法法對2010年1月－2011年7月446例乳腺浸潤性導管癌患者標本進行分子分型，并同時檢測其P53、EGFR、Ki-67等的表達。結果　P53和Ki-67在人類表皮生長因子受體2（HER2）過表達型、基底細胞樣型、未分類型中的表達明顯強于管腔A型及管腔B型（P＜0.05）；HER2過表達型和未分類型中的EGFR表達明顯強于管腔A型及管腔B型（P＜0.05）。結論　在使用雌激素受體、c-erbB-2等指標對浸潤性導管癌進行分子分型時同時檢測P53、EGFR及Ki-67等標記物，有助于更加精準的評估腫瘤的生物學行為及預后，對靶向藥物的個體化治療提供參考和療效預測有重要意義。

引用本文： 王雷,宋林紅,朱鴻,付靜,李科. 不同分子分型乳腺浸潤性導管癌中的P53、表皮生長因子受體及Ki-67的表達及意義. 華西醫學, 2012, 27(9): 1349-1353. doi: 復制

1.	Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
2.	唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應用[J]. 中華病理學雜志, 2009, 38(1): 13-17.
3.	Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
4.	Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
5.	林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導管癌分子亞型與臨床病理特征及預后的關系[J]. 中華病理雜志, 2010, 39(6): 372-376.
6.	袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461.
7.	Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
8.	Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
9.	Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
10.	曾敏. survivin 在乳腺癌中的表達及其與P53基因的關系[J]. 中華實用診斷與治療雜志, 2009, 23(12): 1181-1183.
11.	Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
12.	Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
13.	Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
14.	Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
15.	Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.

1. 　Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
2. 　唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應用[J]. 中華病理學雜志, 2009, 38(1): 13-17.
3. 　Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
4. 　Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
5. 　林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導管癌分子亞型與臨床病理特征及預后的關系[J]. 中華病理雜志, 2010, 39(6): 372-376.
6. 　袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461.
7. 　Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
8. 　Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
9. 　Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
10. 　曾敏. survivin 在乳腺癌中的表達及其與P53基因的關系[J]. 中華實用診斷與治療雜志, 2009, 23(12): 1181-1183.
11. 　Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
12. 　Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
13. 　Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
14. 　Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
15. 　Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.

《華西醫學》

不同分子分型乳腺浸潤性導管癌中的P53、表皮生長因子受體及Ki-67的表達及意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

不同分子分型乳腺浸潤性導管癌中的P53、表皮生長因子受體及Ki-67的表達及意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料